The Evaluation of Renal Tumor Diagnostics in Global Pathology Practice
Bibliographic Information
Authors: Yıldırım N.A.; Farid L.; Akbulut D.; Malik S.; Slisarenko M.; Baydar D.E.; Jikurashvili M.; Tjio E.; Koy Y.; Ertunc O.; Kuthi L.; Montasser A.; Galea L.; Lobo A.; Korentzelos D.; Lagarde-Lenon M.S.; Yaprak Bayrak B.; Biltekin B.; Cheng L.; Williamson S.R.; Sangoi A.R.; Akgul M.
Journal: International Journal of Surgical Pathology
Publisher: SAGE Publications Inc.
Publication Date: 2026-06-29
ISSN: 10668969
DOI: 10.1177/10668969261458406
Scopus: View article on Scopus
PubMed: View article on PubMed
Document Type: Article
Authors and Affiliations
Abstract
Background: The 2022 World Health Organization (WHO) fifth Edition introduced major revisions to renal neoplasm classification, incorporating novel and molecularly defined entities. However, the extent to which these advances are adopted in routine pathology practice remains unclear. This international survey evaluated the global diagnostic work-up of kidney tumors, including access to ancillary tests (immunohistochemistry [IHC], fluorescence in situ hybridization [FISH], next-generation sequencing [NGS]) and familiarity with the current classification. Methods: A 30-question online survey was distributed via SurveyMonkey to pathologists involved in renal tumor diagnostics between January and July 2024. The survey assessed demographics, practice setting, training background, WHO classification familiarity, and availability of IHC and molecular testing. Responses were analyzed using descriptive and inferential statistics. Results: Of 427 respondents, 399 (94.8%) reported encountering kidney tumors and were included, representing 45 countries. The most represented were the United States (18.8%), Egypt (15.8%), Turkey (12.6%), the United Kingdom (8.8%), and India (7.3%). Nearly half (49.4%) had >10 years of practice, 41.1% lacked formal genitourinary pathology training, and 70.7% worked in academic settings. IHC was widely available (96.0%), whereas access to FISH (50.1%) and NGS (43.8%) was limited. High-resource academic centers had significantly greater access to molecular diagnostics than community settings (all p < .001). Kidney-specific molecular panels were available in only 18.1% of institutions. Emerging biomarkers (SDHB, FH, cathepsin K, TFE3, TRIM63) were substantially less available than conventional markers. Although 66.3% reported familiarity with the WHO classification, 33.6% cited barriers such as rapid updates, financial constraints, and workload. Conclusions: Marked global disparities persist in renal tumor diagnostics. While IHC is widely accessible, advanced molecular tools and novel biomarkers remain unevenly distributed, underscoring the need for targeted educational and resource-sharing strategies. © The Author(s) 2026
Keywords
global pathology practice; renal tumors; WHO classification
Citation Information
Scopus Citations: 0
For comprehensive information about the Theodor Bilharz Research Institute (TBRI) , its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments , as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit